Manogepix (APX001A) <i>In Vitro</i> Activity against Candida auris: Head-to-Head Comparison of EUCAST and CLSI MICs
Maiken Cavling Arendrup, Anuradha Chowdhary, Karin Meinike Jørgensen, Joseph Meletiadis
Abstract
Fosmanogepix is a novel prodrug in a new class of antifungal agents. Manogepix is the active moiety. We evaluated the CLSI and EUCAST MICs of manogepix and eight comparators against Candida auris . CLSI M27-A3 susceptibility testing of manogepix was performed for 122 C. auris isolates and compared to CLSI and EUCAST MICs for manogepix and eight comparators. Differences and agreement were calculated for each compound. Wild-type upper limits (WT-ULs; the upper MIC where the wild-type distribution ends) for manogepix and correlations with other drugs’ MICs were determined.
Topics & Concepts
Candida aurisMicrobiologyHead (geology)In vitroBiologyMedicineAntifungalBiochemistryPaleontologyAntifungal resistance and susceptibilityFungal Infections and StudiesPneumocystis jirovecii pneumonia detection and treatment